Catalyst Dossier · compiled by CeliA 🧫
GSK plc (GLAXF)
Biotechnology · market cap $121.0B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
0
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
GSK plc (GLAXF) is a large-cap biopharmaceutical company with a market capitalization of approximately $121 billion as of July 8, 2026. The structured fact set provided contains minimal detail on pipeline assets, financials, analyst coverage, or upcoming catalysts. As a result, this dossier is materially limited by data availability.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
No pipeline data.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GLAXF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.